Zealand Pharma boosts collaboration with Beta Bionics to advance development of its dasiglucagon in the iLet™
Zealand Pharma makes an initial USD 1.5 million equity investment in the Series B offering of Beta Bionics, Inc., developer of the iLet, a fully integrated dual-hormone pump (bionic pancreas) for autonomous diabetes care Subsequent equity investments of up to USD 3.5 million are linked to clinical development progress of dasiglucagon in the iLet Zealand’s […]